These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 11248620)

  • 1. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Roehrborn CG
    Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do alpha-blockers prevent the occurrence of acute urinary retention?
    Hartung R
    Eur Urol; 2001 Mar; 39 Suppl 6():13-8. PubMed ID: 11306896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of medical therapy or surgery on prostatic and bladder resistive indices in patients with benign prostatic hyperplasia.
    Bulut S; Ozden C; Aktas BK; Deren T; Tagci S; Gokkaya CS; Baykam MM; Memis A
    Urol Int; 2015; 94(2):181-6. PubMed ID: 25139617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ
    Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
    Song K; Choo MS; Lee KS; Han JY; Lee YS; Kim JC; Cho JS
    Urology; 2011 May; 77(5):1177-82. PubMed ID: 21256567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
    De Nunzio C; Franco G; Iori F; Leonardo C; Minardi V; Laurenti C
    Urol Int; 2003; 71(1):31-6. PubMed ID: 12845257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.